Macquarie Group LTD Compugen LTD Transaction History

Macquarie Group LTD

$90.3 Billion
Q3 2024

A detailed history of Macquarie Group LTD transactions in Compugen LTD stock. As of the latest transaction made, Macquarie Group LTD holds 1,020,000 shares of CGEN stock, worth $1.56 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,020,000

Previous 1,020,000 -0.0%

Holding current value

$1.56 Million

Previous $1.71 Million 7.76%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$1.75 - $2.95 $35,000 - $59,000	20,000 Added 2.0%	1,020,000 $2.63 Million
Q4 2023 Feb 14, 2024	BUY	$0.53 - $2.0 $77,941 - $294,118	147,059 Added 17.24%	1,000,000 $1.98 Million
Q4 2022 Feb 21, 2023	BUY	$0.58 - $1.2 $94,505 - $195,529	162,941 Added 23.61%	852,941 $614,000
Q2 2022 Aug 15, 2022	SELL	$1.57 - $3.33 $2,915 - $6,183	-1,857 Reduced 0.27%	690,000 $1.28 Million
Q1 2021 May 14, 2021	SELL	$7.67 - $13.77 $3,827 - $6,871	-499 Reduced 0.07%	691,857 $5.94 Million
Q3 2020 Nov 13, 2020	BUY	$14.16 - $19.45 $1.56 Million - $2.14 Million	110,000 Added 18.89%	692,356 $11.3 Million
Q2 2020 Aug 11, 2020	BUY	$6.97 - $17.12 $3.01 Million - $7.4 Million	432,356 Added 288.24%	582,356 $8.75 Million
Q1 2020 May 15, 2020	BUY	$5.79 - $11.83 $868,500 - $1.77 Million	150,000 New	150,000 $1.09 Million
Q1 2019 May 15, 2019	SELL	$2.35 - $4.19 $5,875 - $10,475	-2,500 Closed	0 $0
Q4 2018 Feb 15, 2019	BUY	$2.17 - $3.8 $5,425 - $9,500	2,500 New	2,500 $5,000

Others Institutions Holding CGEN

# of Institutions

Shares Held

13.1M

Call Options Held

79.2K

Put Options Held

12.7K

View Full List

About COMPUGEN LTD

Ticker CGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,624,600
Market Cap $133M
Description
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...

More about CGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.

Account

Macquarie Group LTD Compugen LTD Transaction History